



LETTER TO EDITOR

A Pregnant Woman with Factor V Deficiency

Hassan Mansouritorghabeh*

Immunology Research Center, Inflammation and Inflammatory Disease Division, Mashhad University of Medical Sciences, Mashhad, Iran

ARTICLE INFO

Article History:

Received: 29.09.2021

Accepted: 19.11.2021

*Corresponding author:

H Mansouritorghabeh,
Immunology Research Center,
Inflammation and inflammatory
disease Division, Mashhad University
of Medical Sciences, Mashhad, Iran
Tel: +98 51 38012773
Fax: +98 51 38453339
Email: Mansouritorghabeh@mums.
ac.ir

Please cite this article as: Mansouritorghabeh H. A Pregnant Woman with Factor V Deficiency. IJBC 2021; 13(4): 148.

Dear Editor

I read the fascinating letter entitled: 'All That Glitters is Not Gold: A Pregnant Woman with a Rare Inherited Bleeding Disorder' published in the latest issue Iranian Journal of Blood and Cancer with great attention.¹

Factor V deficiency and other rare bleeding disorder are scarcity and orphan bleeding disorders. Thus, general physicians may rarely encounter with these disorders in clinical practice. If we do not treat them satisfactorily, the hemorrhagic propensity of these diseases may be fatal. Rarity and distribution of affected patients in all countries in the world is one of problem in their clinical practice. In reality, the distribution of small number and various type of coagulation factor concentrates for rare bleeding disorders in a wide country is troublesome in practice for health provider systems.

Patients with factor V deficiency can be treated with ABO matched fresh frozen plasma (FFP) and rich platelet plasma (RPP). Platelets are a noticeable source of coagulation factor V, because of storage of factor V in α granule of the platelets.²

The author declared that these patients might benefit from recombinant Factor V for control of

bleeding episodes. While this may definitely be so, it should be cleared that there is currently no recombinant factor V concentrate on the market. This may be due to scarcity of the disorder and commercial points regarding economically viable.

Fortunately, Kedrion Biopharma Company has recently declared that it is developing recombinant factor V concentrate. This move can pave the way for improved management of both factor V deficiency and combined factor V and VIII deficiency in future.

Conflict of Interest: None declared.

References

1. Aminnejad R. All That Glitters is Not Gold: A Pregnant Woman with a Rare Inherited Bleeding Disorder. IJBC. 2020; 12(2):70-71.
2. Duckers C, Simioni P, Rosing J, Castoldi E. Advances in understanding the bleeding diathesis in factor V deficiency. Br J haematol. 2009;146(1):17-26. doi: 10.1111/j.1365-2141.2009.07708.x. PubMed PMID: 19438479.